Company file Nº 937 / 1000 · Series A · United States · updated 14 Sep 2026
Exai Bio
GTM score
11.4
In its stage
250th of 250 Series A
Ranked against 1000 companies indexed as at 14 Sep 2026. The index grows every month, so a rank can move without a company changing.
What they do
RNA and AI-based liquid biopsy platform for early cancer detection from blood samples
The pillar map
exit criteria metexit criteria partly metexit criteria not metno public signal found
The real colors on all 16 pillars, with each pillar's score, free with an email address.
Our read
We read every map the same way: where the engine is strong, where it's stuck, and what matters most next. Our read on Exai Bio: our read, unlocks with email
What the full report adds
GTM score over time
Think we got Exai Bio wrong? and we will take another look. How we score →